Aurinia Pharmaceuticals Inc (AUPH)
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AUPH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.97B
- P/E (TTM)
- 6.45
- Forward P/E
- 12.67
- EPS (TTM)
- $2.28
- Dividend yield
- None
- 52-week range
- 13.52 – 19.25
- Day range
- 14.63 – 14.97
- Volume / Avg
- 1.34M / 858.74K
- Beta
- —
- Shares outstanding
- 134.00M
52-week range
AUPH stock today
Aurinia Pharmaceuticals (AUPH) closed at $14.70 on Nov 20, down 1.28% (-$0.19), versus the S&P 500's 3.70% decline. At this level, AUPH sits in the middle of its 52-week range of $13.52 to $19.25: 23.6% below the high, set on Jun 24, 2026 and 8.7% above the low. AUPH is down 7.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.3%.
Aurinia Pharmaceuticals trades at 6.4x its trailing twelve-month earnings per share of $2.28. Its forward P/E of 12.7x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Aurinia Pharmaceuticals
Company profileAurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kevin C. Tang
- Headquarters
- Edmonton, AB
- Employees
- 128
- Website
- auriniapharma.com
Financial highlights
Full financialsIn fiscal 2025, Aurinia Pharmaceuticals generated $283.1 million in revenue, up 20.4% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $287.2 million (+4893.1% year over year), for a net margin of 101.5% versus a median of -80.7% in the prior 5 years. Gross margin was 88.5% (up from 88.0%) and operating margin 37.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $283.06M | $235.13M | $175.51M | $134.03M | $45.60M |
| Growth | +20.38% | +33.97% | +30.95% | +193.89% | -9.00% |
| Net income | $287.20M | $5.75M | $-78.02M | $-108.18M | $-180.97M |
| EPS (diluted) | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 |
Analyst forecast
ForecastConsensus (6 analysts)
buy
Avg. price target
$18.50+25.85%
- Strong buy 0
- Buy 4
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.23 vs $0.20
- Surprise
- +15.00%
AUPH news
All AUPH newsAurinia Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HRMYHarmony Biosciences Holdings Inc. | 32.59 | -1.18% | $1.91B | vs AUPH |
| TRVITrevi Therapeutics Inc. | 13.35 | -2.70% | $1.90B | vs AUPH |
| PVLAPalvella Therapeutics Inc. | 142.85 | -2.00% | $2.09B | vs AUPH |
| BHVNBiohaven Ltd. | 12.39 | -9.23% | $1.87B | vs AUPH |
| IMNMImmunome Inc. | 15.69 | -5.54% | $1.85B | vs AUPH |
| VERAVera Therapeutics Inc. Class A | 25.45 | -4.86% | $1.84B | vs AUPH |
| SEPNSepterna Inc. | 38.61 | -1.51% | $1.84B | vs AUPH |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs AUPH |
Indexes, lists and sector
Aurinia Pharmaceuticals stock FAQ
What is Aurinia Pharmaceuticals's stock price today?
AUPH last traded at $14.70 as of Nov 20, 4:00 PM EST, down 1.28% on the day. Prices are delayed at least 15 minutes.
What is AUPH's P/E ratio?
AUPH trades at a trailing P/E ratio of 6.45 and a forward P/E of 12.67.
Who is Aurinia Pharmaceuticals's CEO?
Mr. Kevin C. Tang is the chief executive officer of Aurinia Pharmaceuticals Inc, which has about 128 employees.
What is the AUPH 52-week high?
The 52-week high for AUPH is $19.25 and the 52-week low is $13.52. The stock is currently 23.6% below its high.